| 8.52 -0.17 (-1.96%) | 01-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 14.07 | 1-year : | 16.81 |
| Resists | First : | 12.04 | Second : | 14.39 |
| Pivot price | 10.84  |
|||
| Supports | First : | 8.24 | Second : | 6.85 |
| MAs | MA(5) : | 9.03 |
MA(20) : | 11.43 |
| MA(100) : | 17.31 |
MA(250) : | 12.72 |
|
| MACD | MACD : | -1.6 |
Signal : | -1.5 |
| %K %D | K(14,3) : | 5.5 |
D(3) : | 5 |
| RSI | RSI(14): 24.7 |
|||
| 52-week | High : | 34.27 | Low : | 3.59 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SCLX ] has closed above bottom band by 10.7%. Bollinger Bands are 31.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9.08 - 9.17 | 9.17 - 9.22 |
| Low: | 8.15 - 8.26 | 8.26 - 8.33 |
| Close: | 8.39 - 8.57 | 8.57 - 8.68 |
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.
Fri, 30 Jan 2026
Scilex Holding Company Invests $20 Million in Quantum Scan Holdings, Inc. to Boost Medical Technology Development - Quiver Quantitative
Fri, 23 Jan 2026
Scilex (NASDAQ:SCLX) Trading Up 8.8% - Time to Buy? - MarketBeat
Sat, 10 Jan 2026
Not Many Are Piling Into Scilex Holding Company (NASDAQ:SCLX) Stock Yet As It Plummets 26% - simplywall.st
Wed, 17 Dec 2025
Retail investors invested in Scilex Holding Company (NASDAQ:SCLX) copped the brunt of last week's US$12m market cap decline - simplywall.st
Mon, 08 Dec 2025
Scilex Holding Company's (NASDAQ:SCLX) top owners are retail investors with 57% stake, while 24% is held by private companies - Yahoo Finance
Wed, 26 Nov 2025
Datavault AI Announces Closing of the Second Tranche of Scilex Holding Company’s Previously Announced Equity Financing - Datavault AI
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 0 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 3.65e+006 (%) |
| Held by Institutions | 17.5 (%) |
| Shares Short | 135 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.5916e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 766.2 % |
| Return on Equity (ttm) | -87.5 % |
| Qtrly Rev. Growth | 4.036e+007 % |
| Gross Profit (p.s.) | -19.5 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 2.0058e+007 |
| Qtrly Earnings Growth | -40.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 24 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.4 |
| Dividend | 0 |
| Forward Dividend | 155350 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|